ALRTF (ALR Technologies SG) 3-Year RORE % : 37.50% (As of Dec. 2025)


What is ALR Technologies SG 3-Year RORE %?

ALR Technologies SG ALRTF +18.59% 3-Year RORE % is 37.50 as of Dec. 2025. The stock has 3 warning signs investors should review. Among 781 Medical Devices & Instruments companies, ALR Technologies SG ranks better than 82.2% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. ALR Technologies SG's 3-Year RORE % for the quarter that ended in Dec. 2025 was 37.50%.

The industry rank for ALR Technologies SG's 3-Year RORE % or its related term are showing as below:

ALRTF's 3-Year RORE % is ranked better than
82.2% of 781 companies
in the Medical Devices & Instruments industry
Industry Median: -4.27 vs ALRTF: 37.50

ALR Technologies SG  (OTCPK:ALRTF) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


ALR Technologies SG 3-Year RORE % Related Terms


ALR Technologies SG 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for ALR Technologies SG's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ALR Technologies SG 3-Year RORE % Chart

ALR Technologies SG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -25.00 0.00 -20.00 16.67 37.50

ALR Technologies SG Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -20.00 -20.00 16.67 28.57 37.50

ALRTF vs CODX, SINT, HSCS: 3-Year RORE % Comparison

For the Medical Devices subindustry, ALR Technologies SG's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ALR Technologies SG 3-Year RORE % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ALR Technologies SG's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where ALR Technologies SG's 3-Year RORE % falls into.



ALR Technologies SG 3-Year RORE % Calculation

ALR Technologies SG's 3-Year RORE % for the quarter that ended in Dec. 2025 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -0.04--0.01 )/( -0.08-0 )
=-0.03/-0.08
=37.50 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of 37.50 mean?
ALR Technologies SG (ALRTF) has a 3-Year RORE % of 37.50 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on ALR Technologies SG and its competitors. According to the industry distribution chart, ALR Technologies SG ranks #139 out of 781 companies in the Medical Devices & Instruments industry, placing it in the top 17.8%.
Is ALR Technologies SG's 3-Year RORE % too high?
ALR Technologies SG's current 3-Year RORE % is 37.50. Based on the distribution chart, ALR Technologies SG ranks #139 out of 781 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers.
How does ALR Technologies SG's 3-Year RORE % compare to CODX and SINT?
According to the Medical Devices & Instruments industry distribution chart, ALR Technologies SG ranks #139 out of 781 companies for 3-Year RORE %. This places ALR Technologies SG in the top 18% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Devices & Instruments company?
A good 3-Year RORE % depends on the Medical Devices & Instruments industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on ALR Technologies SG and its competitors. ALR Technologies SG's current 3-Year RORE % is 37.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ALR Technologies SG stock overvalued right now?
ALR Technologies SG (ALRTF) has a current 3-Year RORE % of 37.50. The current 3-Year RORE % is 37.50. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For ALR Technologies SG (ALRTF), the current 3-Year RORE % is 37.50 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ALR Technologies SG Business Description

Address 9 Raffles Place, No. 26-01, Republic Plaza, Singapore, SGP, 048619
ALR Technologies SG Ltd is a medical device company that focuses on commercializing its Health-e-Connect System. The company is a data management company that developed a comprehensive approach to diabetes care that includes an FDA-cleared and HIPAA-compliant Diabetes Solution product that can collect data from BGM and CGM; a patent-pending Predictive A1C algorithm to track treatment success between lab reports; and an FDA-cleared Insulin Dosing Adjustment program. Geographically, it operates in the United States and Singapore.